Linde/Praxair asset package sees Italian additions
30 APR 2018
Linde [ETR:LIN] and Praxair [NYSE:PX] have added Praxair’s Italian business to the package of assets being marketed to pre-empt European Commission (EC) concerns on their proposed tie-up, it is understood.
The parties are yet to submit a formal offer to the EC in the context of the authority’s Phase II review of the deal.
The most recent additions to the package - contained in a supplementary information memorandum - do not include assets in Eastern Europe, where the parties also have overlapping businesses, it is understood.
Media reports previously flagged Praxair’s joint ventures in Italy, Austria and Eastern Europe as a potential hurdle in designing a remedy package.
Praxair has a majority stake in Italian company Rivoira and a minority one in Italian company SIAD. The latter has a presence in a number of Eastern European countries including Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia. Linde is also present in Italy.
The boundaries of the European package still appear to be fluid, and there is no indication on which remedy assets will be finally included in the package, it is understood. The situation is similar for the assets marketed in the US, where parties are believed to still be talking to the Federal Trade Commission (FTC), it was said.
At least four bidders are thought to be in the race at present, it was said. Financial buyers are seen likely to bid for global assets - both EU and US - due to their financial firepower, it was added. But the sale process is being run in parallel in the two regions, it is understood.
Based on the information the seller gave so far, it doesn’t look like they are set on a global solution, a source familiar with the matter indicated. Potential buyers are being invited to bid for both regional and US packages, the source said.
Linde and Praxair have selected second-round bidders, according to a media report. CVC/Messer Group, Carlyle, Onex and Blackstone have been invited to submit further bids.
The shortlisted bidders are attending management presentations and having access to due diligence, it was said.
There has been some movement in the EC review lately, it is understood. The parties are believed to have met the EC at least once in the past month, a person briefed on the matter said.
In a few weeks the EC will need to decide whether to issue a statement of objections (SO), a formal document outlining concerns on the deal. In complex deals such as, for example, the recent case of Monsanto [ETR:BAS]/Bayer[ETR:BAYN], the EC sometimes prefers to issue an SO to maintain leverage in the review, even if a remedy package is almost on the table, it was noted.
An SO does not prejudge the outcome of an investigation and is sometimes viewed positively as it spells out EC concerns clearly, as previously reported.
Linde declined to comment. Spokespeople for Praxair were not reachable in European business hours.